Zealand Pharma A/S (ZEAL): Price and Financial Metrics
ZEAL Price/Volume Stats
| Current price | $17.59 | 52-week high | $32.94 |
| Prev. close | $17.38 | 52-week low | $9.93 |
| Day low | $17.47 | Volume | 2,100 |
| Day high | $18.07 | Avg. volume | 4,965 |
| 50-day MA | $17.62 | Dividend yield | N/A |
| 200-day MA | $17.38 | Market Cap | 818.60M |
ZEAL Stock Price Chart Interactive Chart >
Zealand Pharma A/S (ZEAL) Company Bio
Zealand Pharma A/S, a biotech company, engages in the discovery, design, and development of novel peptide-based medicines in Denmark. The company was founded in 1997 and is based in Copenhagen, Denmark.
Latest ZEAL News From Around the Web
Below are the latest news stories about ZEALAND PHARMA A that investors may wish to consider to help them evaluate ZEAL as an investment opportunity.
Needham Sticks to Their Buy Rating for Zealand Pharma (ZEAL)E ratio of -4.51. |
Zealand Pharma’s (NASDAQ:ZEAL) Phase 3 SBS Trial Sees Positive ResultsBiotechnology company Zealand Pharma (NASDAQ:ZEAL) has delivered positive topline results from the Phase 3 trial of glepaglutide for the treatment of short bowel syndrome (SBS). The trial met its primary endpoint and the twice-weekly dosing regimen showed a statistically significant decrease in weekly parental support at 24 weeks. The treatment was deemed safe and was well tolerated. |
Total number of shares and voting rights in Zealand Pharma at September 30, 2022Company announcement – No. 42 / 2022 Total number of shares and voting rights in Zealand Pharma at September 30, 2022 Copenhagen, DK and Boston, MA, September 30, 2022 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, in accordance with section 32 of the Danish Capital Markets Act, announces the total number of shares and voting rights in the Company at th |
Zealand Pharma Announces Positive Results from Phase 3 Trial of Glepaglutide in Patients with Short Bowel Syndrome (EASE 1)Company announcement – No. 41 / 2022 Zealand Pharma Announces Positive Results from Phase 3 Trial of Glepaglutide in Patients with Short Bowel Syndrome (EASE 1) Glepaglutide treatment met the primary endpoint with twice weekly dosing achieving a statistically significant reduction in weekly parenteral support volume by 5.13 Liters/week from baseline at 24 weeks66% of patients in the twice weekly group had a clinically meaningful response (>20% reduction in parenteral support volume)In total 9 pa |
Zealand Pharma Announces Oral Presentation of Phase 2 Data for BI 456906 at the 58th Annual Meeting of the European Association for the Study of Diabetes (EASD)Press release – No. 6 / 2022 Zealand Pharma Announces Oral Presentation of Phase 2 Data for BI 456906 at the 58th Annual Meeting of the European Association for the Study of Diabetes (EASD) BI 456906 effectively lowered HbA1c up to -1.88% at week 16 in patients with type 2 diabetes in the Phase 2 clinical trialPreclinical pharmacology of BI 456906 supports ongoing Phase 2 studies in obesity or non-alcoholic steatohepatitis Copenhagen, Denmark and Boston MA, U.S. September 21, 2022 – Zealand Phar |
ZEAL Price Returns
| 1-mo | N/A |
| 3-mo | N/A |
| 6-mo | N/A |
| 1-year | 0.00% |
| 3-year | -52.59% |
| 5-year | 6.48% |
| YTD | N/A |
| 2022 | 0.00% |
| 2021 | -40.62% |
| 2020 | 8.25% |
| 2019 | 185.96% |
| 2018 | -14.63% |
Continue Researching ZEAL
Want to do more research on Zealand Pharma A's stock and its price? Try the links below:Zealand Pharma A (ZEAL) Stock Price | Nasdaq
Zealand Pharma A (ZEAL) Stock Quote, History and News - Yahoo Finance
Zealand Pharma A (ZEAL) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...